Search Results for "Levosimendan Intermittent"
Original Source: Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure
The purpose of this study is to determine whether the treatment strategy of long-term intermittent every 30 days, continuous intravenous infusion for 24 hours of Levosimendan, associated to optimal contemporary treatment for advanced heart failure reduce the incidence of admission for heart failure worsening at 12 months follow up, compared with the strategy based solely in the optimal contemporary treatment for advanced heart failure.
Matching Channels
None
Matching News
IV Levosimendan Mixed Blessing for Outpatients (CME/CE)
LISBON (MedPage Today) -- Repeated doses of IV levosimendan given to outpatients with end-stage heart failure failed to improve functional capacity or quality of life, despite some positive outcomes,...
Levosimendan improves event free survival by 50 percent in end-stage heart failure
(European Society of Cardiology) Ambulatory levosimendan improves event free survival by 50 percent compared to placebo, according to results from the LevoRep Study presented today during the late bre...
In End-Stage Heart Failure, Levosimendan Improves Event Free Survival By 50 Percent
Ambulatory levosimendan improves event free survival by 50% compared to placebo, according to results from the LevoRep Study presented during a late breaking trial session of the Heart Failure Congres...
Continuous vs Intermittent HIV Treatment
Is intermittent treatment safe and effective for HIV infected patients? AIDS
Prostate cancer: Intermittent ADT—tales from a 27-year odyssey
Intermittent androgen deprivation can reduce treatment-related adverse effects in men with prostate cancer. Data from the recent SWOG-9346 trial show a nonsignificant improvement in median overall sur...
Prostate cancer study casts doubts over intermittent dosing approach
Intermittent androgen deprivation in prostate cancer may not be as effective as continuous therapy, according to the authors of an international trial published in the New England Journal of Medicine...
Clinical QuestionDo antiplatelet therapies reduce risk of all-cause mortality, cardiovascular disease (CVD) mortality, and cardiovascular events in patients with intermittent claudication? Which antip...
uniQure initiates phase I study in acute intermittent porphyria
uniQure, a company that researches and develops human gene based therapies, has initiated its phase I clinical trial in acute intermittent porphyria (AIP).
Matching PubMed Articles
Acetylation status does not affect levosimendan's hemodynamic effects in heart failure patients.
Abstract Objective. Levosimendan is indicated for acute heart failure. The formation of levosimendan's active metabolite OR-1896 is dependent on the acetylator status. We evaluated whether acetylator...
We investigated both the effect of levosimendan and the role of oxidant/antioxidant status and trace element levels in the pulmonary artery of rats. Fourteen male Wistar albino rats were randomly divi...
Oral levosimendan improves filling pressure and systolic function during long-term treatment.
Abstract Objectives. Oral levosimendan improves ventricular function in short-term clinical trials. The effects of long-term treatment with oral levosimendan were investigated on echocardiographic par...
We report the use of levosimendan in two febrile, neutropenic children with cancer - one post bone marrow transplant - with acute heart failure following chemotherapy. Initial management with epinephr...
Multiple signalling pathways underlie the protective effect of levosimendan in cardiac myocytes.
Levosimendan is a cardiovascular drug for the treatment of acute and decompensated heart failure. The current weight of evidence on the cardioprotective effects of levosimendan originates from whole h...
